Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/13/7170 |
| _version_ | 1797527982940618752 |
|---|---|
| author | Victor Chien-Chia Wu Yan-Rong Li Chao-Yung Wang |
| author_facet | Victor Chien-Chia Wu Yan-Rong Li Chao-Yung Wang |
| author_sort | Victor Chien-Chia Wu |
| collection | DOAJ |
| description | Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of insulin. This class of drugs has the advantages of no clinically relevant hypoglycemia and working in synergy when combined with currently available anti-diabetic drugs. While improving sugar level control in these patients, SGLT2 inhibitors also have the advantages of blood-pressure improvement and bodyweight reduction, with potential cardiac and renal protection. In randomized control trials for patients with diabetes, SGLT2 inhibitors not only improved cardiovascular and renal outcomes, but also hospitalization for heart failure, with this effect extending to those without diabetes mellitus. Recently, dynamic communication between autophagy and the innate immune system with Beclin 1-TLR9-SIRT3 complexes in response to SGLT2 inhibitors that may serve as a potential treatment strategy for heart failure was discovered. In this review, the background molecular pathways leading to the clinical benefits are examined in this new class of anti-diabetic drugs, the SGLT2 inhibitors. |
| first_indexed | 2024-03-10T09:51:37Z |
| format | Article |
| id | doaj.art-380819a43f634c899daf3960affbf5c0 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T09:51:37Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-380819a43f634c899daf3960affbf5c02023-11-22T02:41:28ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-012213717010.3390/ijms22137170Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac ProtectionVictor Chien-Chia Wu0Yan-Rong Li1Chao-Yung Wang2Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City 33305, TaiwanSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan City 33302, TaiwanDivision of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City 33305, TaiwanSodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of insulin. This class of drugs has the advantages of no clinically relevant hypoglycemia and working in synergy when combined with currently available anti-diabetic drugs. While improving sugar level control in these patients, SGLT2 inhibitors also have the advantages of blood-pressure improvement and bodyweight reduction, with potential cardiac and renal protection. In randomized control trials for patients with diabetes, SGLT2 inhibitors not only improved cardiovascular and renal outcomes, but also hospitalization for heart failure, with this effect extending to those without diabetes mellitus. Recently, dynamic communication between autophagy and the innate immune system with Beclin 1-TLR9-SIRT3 complexes in response to SGLT2 inhibitors that may serve as a potential treatment strategy for heart failure was discovered. In this review, the background molecular pathways leading to the clinical benefits are examined in this new class of anti-diabetic drugs, the SGLT2 inhibitors.https://www.mdpi.com/1422-0067/22/13/7170SGLT2 inhibitorscardiac protectionautophagyinnate immunity |
| spellingShingle | Victor Chien-Chia Wu Yan-Rong Li Chao-Yung Wang Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection International Journal of Molecular Sciences SGLT2 inhibitors cardiac protection autophagy innate immunity |
| title | Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection |
| title_full | Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection |
| title_fullStr | Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection |
| title_full_unstemmed | Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection |
| title_short | Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection |
| title_sort | impact of sodium glucose co transporter 2 inhibitors on cardiac protection |
| topic | SGLT2 inhibitors cardiac protection autophagy innate immunity |
| url | https://www.mdpi.com/1422-0067/22/13/7170 |
| work_keys_str_mv | AT victorchienchiawu impactofsodiumglucosecotransporter2inhibitorsoncardiacprotection AT yanrongli impactofsodiumglucosecotransporter2inhibitorsoncardiacprotection AT chaoyungwang impactofsodiumglucosecotransporter2inhibitorsoncardiacprotection |